Area of research
Water Science and Technology · Pathology and Forensic Medicine
Research interest
Research interests include Membrane Separation Technologies, Advanced oxidation water treatment, Lymphoma Diagnosis and Treatment, and Chronic Lymphocytic Leukemia Research.
Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors (2024)
Proteomic and metabolomic profiling of plasma uncovers immune responses in patients with Long COVID-19
Chinese expert consensus on integrated case management by a multidisciplinary team in CAR-T cell therapy for lymphoma
Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma
Improving gel properties of egg white protein using coconut endosperm dietary fibers modified by ultrasound and dual enzymolysis combined with carboxymethylation or phosphate crosslinking
ABLs and TMKs are co-receptors for extracellular auxin
VIRMA promotes nasopharyngeal carcinoma, tumorigenesis, and metastasis by upregulation of E2F7 in an m6A-dependent manner
Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations
A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
Chinese Society of Anesthesiology Expert Consensus on Anesthetic Management of Cardiac Surgical Patients With Suspected or Confirmed Coronavirus Disease 2019
Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial
Efficacy and Safety of Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia
Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial
Epidemiology and treatment of invasive fungal diseases in patients with multiple myeloma: findings from a multicenter prospective study from China
Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial